Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


VUMC Joins Effort to Stop Spread of Two Deadly Viruses


 
James Crowe Jr., MD

Researchers at Vanderbilt University Medical Center (VUMC) are participating in a national effort to develop vaccines and other treatments as countermeasures to prevent the spread of two emerging and deadly viruses -- Nipah and Hendra.

A five-year grant of up to $24.5 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was announced this week. Christopher Broder, PhD, at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, is heading the effort.

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at VUMC, said his group's role is to identify, develop and characterize anti-Nipah/Hendra human monoclonal antibodies directly from naturally infected human survivors.

These antibodies "will be used to understand and define the basic mechanisms by which naturally occurring antibodies kill Nipah and Hendra viruses," Crowe said in a news release.

Broder and Thomas Geisbert, PhD, at the University of Texas Medical Branch in Galveston, and his colleagues previously described a prototype anti-Nipah/Hendra monoclonal antibody that has been successfully used on an emergency basis in more than a dozen individuals.

Crowe and his team will build on these preliminary results with a synthetic antibody to isolate fully human antibodies directly from the circulating white blood cells of the immune subjects, to identify optimal therapeutic antibodies.

Other partners in the NIAID grant include John Eldridge, PhD, chief scientific officer-vaccines at Profectus Biosciences, a clinical-stage vaccine development company based in Baltimore, Maryland, and Larry Zeitlin, PhD, president of Mapp Biopharmaceutical Inc., a San Diego-based firm that will prepare the new antibodies for human safety testing.

Hendra was identified in 1994 during an outbreak of respiratory and neurologic disease in horses and humans in Australia. Although Hendra infection in humans is rare, the risk of death approaches 60 percent, according to the U.S. Centers for Disease Control and Prevention (CDC).

Nipah, identified in 1999 during an outbreak of encephalitis and respiratory illness among pig farmers in Malaysia and Singapore, is an epidemic threat that kills up to 40 percent of its victims.

Last year the virus was placed on the World Health Organization's list of "priority diseases" for urgent research and development because of its high public health risk and potential to be used as a bioterrorism agent.

The NIAID grant (AI142764) is part of the institute's collaborative Center of Excellence for Translational Research (CETR) program established in 2014 to advance development of medical countermeasures, including vaccines and immunotherapeutics, against emerging and re-emerging infectious diseases.

Crowe and his team currently are participating in another CETR grant led by Geisbert to advance the treatments of deadly hemorrhagic fever viral infections caused by Ebola and Marburg viruses.

He also is principal investigator of a cooperative agreement between VUMC and the U.S. Defense Advanced Research Projects Agency (DARPA) announced last year to develop methods for preventing the global spread of viruses like chikungunya and Zika. The five-year agreement is worth up to $28 million.

Crowe is the Ann Scott Carell Professor in departments of Pediatrics and of Pathology, Microbiology & Immunology in the Vanderbilt University School of Medicine.

He and his colleagues have isolated human monoclonal antibodies for many pathogenic viruses and pioneered the rational design of neutralizing antibody treatments and vaccines, some of which have progressed to clinical trials.

 
Share:

Related Articles:


Recent Articles

New Study Identifies Gaps in Treatment for Opioid Use Disorder as Overdose Emergencies Soar

Opioid overdose deaths have reached record highs and emergency physicians have a vital role in potentially saving these patients by prescribing Medication Assisted Treatment (MAT) such as buprenorphine, and by prescribing naloxone, a rapid-acting medicine to reverse an overdose.

Read More

HealthStream Acquires Rievent Technologies

Leveraging its hStream open architecture, HealthStream expands its ecosystem with a powerful continuing education management and delivery application

Read More

INTERNATIONAL VOLUNTEER DAY: LOCAL PEDIATRICIAN TERRI WHITE DEDICATES TIME TO HELP CHILDREN WORLDWIDE

International Volunteer Day is a global celebration of volunteers. It takes place every year on December 5 to shine a light on the impact of volunteer efforts everywhere.

Read More

Tivity Health Takes Meaningful Steps to Keep Seniors Engaged, Connected

At first glance, SilverSneakers might appear to be 'just' a fitness class ... but dig a bit deeper, and it's clear this class is actually a community keeping participants active and engaged.

Read More

AMA Adopts Policy to Combat Public Health Disinformation by Health Care Professionals

New policy aims to address spread of rampant disinformation amid COVID-19 pandemic

Read More

AMA Adopts Policy Aimed at Strengthening U.S. Public Health Infrastructure, Opposing Limits Placed on Public Health Officials

New policy calls for consistent, sustainable funding, a robust public health workforce, and data modernization

Read More

Managing Risk of Cyber Incidents

Cyber threats are here to stay -- and they continue to be one of the topics keeping senior management up at night. With breaches and ransomware attacks still occurring at high rates, the healthcare industry continues to be significantly impacted.

Read More

American Cancer Society, Meharry Team Up to Change the Narrative

Meharry Medical College is one of four HBCUs partnering with the American Cancer Society.

Read More

Navigating Cancer Care

Nashville startup Thyme Care is proving to be an innovator in the cancer navigation space.

Read More

ONcology Rounds

New treatments, research and leadership - Middle Tennessee has a lot going on in oncology care.

Read More

Email Print
 
 

 

 


Tags:
Health Disparities, Hendra, Infectious Disease, James Crowe Jr., Nipah, Population Health, Social Determinants of Health, Vaccines, Vanderbilt University Medical Center, VUMC
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: